Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
- Apr 18, 2018 (filed on Apr 19, 2018)Insider Name:Starr Kevin POwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-24,000Price:$168.28
- Apr 17, 2018 (filed on Apr 19, 2018)Insider Name:Starr Kevin POwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-35,000Price:$169.25
- Apr 02, 2018 (filed on Apr 04, 2018)Insider Name:Cloonan MichaelOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:36,000Price:--
- Apr 02, 2018 (filed on Apr 04, 2018)Insider Name:Iguchi KimiOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:31,500Price:--
- Apr 02, 2018 (filed on Apr 04, 2018)Insider Name:Cook Anne MarieOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:31,500Price:--
- Apr 02, 2018 (filed on Apr 04, 2018)Insider Name:Robichaud AlbertOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:31,500Price:--
- Apr 02, 2018 (filed on Apr 04, 2018)Insider Name:Kanes StephenOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:27,000Price:--
- Apr 02, 2018 (filed on Apr 04, 2018)Insider Name:Jonas Jeffrey MOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:90,000Price:--
- Mar 06, 2018 (filed on Mar 08, 2018)Insider Name:Paul Steven MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-58,139Price:$172.00
- Feb 16, 2018 (filed on Feb 20, 2018)Insider Name:Starr Kevin POwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:J - Other transaction# or value acquired/disposed of:-510,554Price:--
Filings by filing date
- Apr 18, 2018 (filed on Apr 19, 2018)Insider Name:Starr Kevin POwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-24,000Price:$168.28
- Apr 17, 2018 (filed on Apr 19, 2018)Insider Name:Starr Kevin POwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-35,000Price:$169.25
- Apr 02, 2018 (filed on Apr 04, 2018)Insider Name:Cloonan MichaelOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:36,000Price:--
- Apr 02, 2018 (filed on Apr 04, 2018)Insider Name:Iguchi KimiOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:31,500Price:--
- Apr 02, 2018 (filed on Apr 04, 2018)Insider Name:Cook Anne MarieOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:31,500Price:--
- Apr 02, 2018 (filed on Apr 04, 2018)Insider Name:Robichaud AlbertOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:31,500Price:--
- Apr 02, 2018 (filed on Apr 04, 2018)Insider Name:Kanes StephenOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:27,000Price:--
- Apr 02, 2018 (filed on Apr 04, 2018)Insider Name:Jonas Jeffrey MOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:90,000Price:--
- Mar 06, 2018 (filed on Mar 08, 2018)Insider Name:Paul Steven MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-58,139Price:$172.00
- Feb 16, 2018 (filed on Feb 20, 2018)Insider Name:Starr Kevin POwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:J - Other transaction# or value acquired/disposed of:-510,554Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 215 1st St CAMBRIDGE MA 02142-1213 |
Tel: | N/A |
Website: | www.sagerx.com |
IR: | See website |
Key People | ||
Kevin P. Starr Independent Chairman of the Board | Thomas D. Anderson Chief Commercial Strategy Officer | Jeffrey M. Jonas President, Chief Executive Officer, Director |
Kimi E. Iguchi Chief Financial Officer, Treasurer | Anne Marie Cook Senior Vice President, General Counsel | Amy Schacterle Senior Vice President - Regulatory Affairs and Quality Assurance |
Christopher Silber Senior Vice President - Clinical Development | Albert J. Robichaud Chief Scientific Officer | Frank Sanders Vice President of Sales and Marketing | Paul Hodgkins Vice President - Health Economics and Outcomes Research and Value Demonstration |
Business Overview |
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors. |
Financial Overview |
For the fiscal year ended 31 December 2017, SAGE Therapeutics Inc revenues was not reported. Net loss increased 70% to $270.1M. Higher net loss reflects R & D exp increase of 74% to $190.4M (expense), General & admi increase of 71% to $47.2M (expense), Stock-based Compensation in R&D increase of 78% to $19.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$4.75 to -$7.09. |
Employees: | 257 as of Dec 31, 2017 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $6,257M as of Dec 31, 2017 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2017 |
EBITDA (TTM): | -$272.63M as of Dec 31, 2017 |
Net annual income (TTM): | -$270.12M as of Dec 31, 2017 |
Free cash flow (TTM): | -$220.64M as of Dec 31, 2017 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 45,777,940 as of Feb 15, 2018 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |